GlassScriptPhysician profile
Stephen P Kajencki
NPI 1073521753
$2,645.69
in general payments reported to CMS, 2019-2025
29 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $523 · 2021: $269 · 2022: $260 · 2023: $511 · 2024: $139 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $530.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $335.46 | 2019-2024 | Farxiga, Fasenra, Airsupra |
| Pfizer INC. | $266.55 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $220.24 | 2019-2022 | |
| Lilly USA, LLC | $215.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $199.67 | 2019-2023 | Bexsero, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.62 | 2019-2025 | Jardiance |
| Abbott Laboratories | $153.73 | 2019-2023 | Freestyle Libre 2 |
| Abbvie INC. | $83.20 | 2019-2023 | |
| Hologic Sales and Service, LLC | $53.83 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Lifescan, INC. | $45.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.60 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $39.25 | 2022-2023 | Rexulti |
| Verona Pharma, INC. | $29.80 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $25.07 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $21.08 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.33 | 2021 | |
| Indivior INC. | $20.07 | 2024 | Sublocade |
| Corcept Therapeutics | $18.64 | 2019 | |
| Astellas Pharma US INC | $18.60 | 2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $18.49 | 2023 | Gvoke Hypopen |
| Janssen Biotech, INC. | $17.94 | 2019 | |
| Cranial Technologies, INC | $17.48 | 2023 | Doc Band |
| Lucid Diagnostics INC. | $15.56 | 2024 | |
| Kaleo, INC. | $15.24 | 2019 | |
| Merck Sharp & Dohme LLC | $15.06 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.63 | 2025 | Zoryve |
| Seqirus USA INC | $13.31 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Genentech USA, INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Kajencki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.